Notably, RB1-mutant and KDR-amplified GBM IDH-WT subgroups harbored a distinct PFS and OS, in which RB1-mutant patients had doubled the PFS (11.9 vs 5.8 months, P = .0691) and OS (23.5 vs 11.4 months, P = .0002) compared to KDR-amplified GBM IDH-WT (Figure 2A and B). This evidence concerns the gene KDR and glioblastoma.